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Abstract Therapy of primary focal segmental glomerulo-
sclerosis (FSGS) in children incorporates conservative
management and immunosuppression regimens to control
proteinuria and preserve kidney function. In long-term
cohort studies in adults and children with primary FSGS,
renal survival has been directly associated with degree of
proteinuria control. This educational article reviews the
current therapeutic approach toward children with primary
FSGS.
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Introduction
Focal segmental glomerulosclerosis (FSGS) is a histologic
finding that may result from a variety of insults to the
kidney. FSGS typically presents with proteinuria and has a
high risk of progressive loss of renal function [1].
Treatment of secondary forms of FSGS targets control of
the underlying condition. Therapy of primary FSGS
incorporates conservative management and immunosup-
pression regimens to control proteinuria and preserve
kidney function. In long-term cohort studies in adults and
children with primary FSGS, renal survival has been
directly associated with degree of proteinuria control
(Fig. 1)[ 2, 3]. Patients who are resistant to therapies have
a significant likelihood of progressing to end-stage renal
disease (ESRD) and are a group in need of novel therapies
to delay or prevent this outcome [4].
Genetic considerations
An undefined proportion of patients with classically defined
primary FSGS harbor genetic mutations in podocyte-
specific genes such as nephrin, podocin, α-actinin-4, and
CD2AP [5, 6]. There are conflicting reports about the
effectiveness of immune-based therapy in the setting of
these mutations, but the likelihood of a positive response
may be low [7]. Although mutation-linked cases of FSGS
may have a lower response rate to conventional immuno-
modulatory treatment, these patients still manifest the
progressive fibrosis that is observed in nongenetic FSGS.
Nonimmunosuppressive therapy
Diuretic therapy
Control of edema in nephrotic syndrome allows not only
cosmetic improvement but is expected to decrease pulmo-
nary effusions, decrease ascites, and lower the risk of
peritonitis and skin-related problems from edema. Over-
aggressive diuresis in patients with intravascular depletion
may be a risk factor, however, in developing thrombotic
complications and acute renal insufficiency.
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Bethesda, MD, USALoop diuretics are often required for control of edema in
patients with proteinuria in the nephrotic range. Delivery of
the diuretic to the site of action (lumen of the tubule) is
often impaired in nephrotic syndrome due to decreased
glomerular filtration rate (GFR), increased binding of the
diuretic to intraluminal albumin, and/or decreased delivery
of sodium to sites of diuretic activity. An increase of
sodium reabsorption in the distal tubule in response to loop
diuretic activity may add to resistance to loop diuretics.
This distal compensatory mechanism may be diminished by
the use of a combination of loop and distal diuretics
(thiazides) [8]. Though the addition of aldosterone inhib-
itors (spironolactone) is theoretically attractive under the
theory that edema is in part driven by aldosterone, it is
Fig. 1 a Kaplan–Meyer analy-
sis of the risk of end-stage renal
disease (ESRD) by proteinuria
remission status in children with
primary focal segmental glo-
merulosclerosis (FSGS). b Kid-
ney survival by proteinuria
remission status in adults with
primary FSGS. CR complete
remission, PR partial remission,
NR no remission
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are clinically helpful to control edema [9–11] An additional
advantage to the use of aldosterone inhibitors such as
spironolactone is suggested by the antifibrotic properties of
these agents, which will be discussed below [12].
Combined albumin and furosemide therapy for anasarca
has been studied, as well. Na et al. showed evidence for a
mild increase in water diuresis but little evidence that the
concomitant use of albumin adds to the natruretic effect of
furosemide [13, 14]. Fliser et al. [15] showed a moderate
(20%) increase in water and salt excretion when comparing
albumin and furosemide to furosemide alone. Haws et al.
[16] also showed a mild but transient benefit of albumin
and furosemide therapy but commented on the potential
serious complications of hypertension, respiratory distress,
congestive heart failure, and electrolyte disturbances. Thus,
the combination of albumin and furosemide infusions,
whether in combination or sequential, may provide a small
transient benefit in the therapy of children with severe
edema [17].
Treatment of hyperlipidemia
For patients who become nephrotic from the progression of
FSGS, hyperlipidemia is an almost universal finding.
Whether the hyperlipidemia associated with nephrotic
syndrome should be specifically targeted for treatment in
children separately from nephrotic syndrome treatment
itself has been a question for more than 20 years. The
childhood origin of atherosclerotic disease and increased
risk for cardiovascular disease secondary to chronic kidney
disease supports an interventional approach.
The report of the expert panel on blood cholesterol levels
in children and adolescents [18] from the National
Cholesterol Education Program (NCEP) defined categories
of hypercholesterolemia in children for total cholesterol and
low-density lipoprotein (LDL) cholesterol levels. High
levels for total cholesterol were defined as ≥200 mg/dl
and for LDL cholesterol as ≥130 mg/dl. Dietary treatment
of hyperlipidemia is the first-line intervention. In adults
with nephrotic syndrome, soy-based vegetarian diets and
supplemented low protein diets have been shown to have
potential benefits, decreasing both proteinuria and choles-
terol, but have not been shown to slow the decline in GFR
[19, 20]. Dietary therapy for dyslipidemia has been
effective in reducing lipid levels in children with primary
lipid disorders [21].
Based on the report from the NCEP, pharmacologic
therapy for children ages 10 years and older should be
considered after an adequate trial of diet therapy if LDL
cholesterol remains ≥160 mg/dl in children with significant
risk for cardiovascular disease, as is seen in children with
FSGS. Recommendations for pharmacologic therapy for
hyperlipidemia in children from the report suggested that
bile acid sequestrants cholestyramine and colestipol should
be the first-line agents for treating children with lipid
disorders [18]. This was due mainly to concerns about the
safety of 3-hydroxy-3-methylglutaryl coenzyme A (HMG
CoA) reductase inhibitors (statins) in children. While they
are effective in lowering cholesterol and are relatively safe,
bile acid sequestrants pose particular problems in children.
They are not very palatable, and they may affect absorption
of other medications being used, including thiazide
diuretics, propranolol, corticosteroids, thyroid hormones,
and loop diuretics. A new medication in this category,
colesevelam, apparently does not have these problems
but is not approved for use in children.
Since the NCEP report in 1992, several studies have
been published suggesting that statins are safe in children as
young as 4 years of age with familial hypercholesterolemia
and do not adversely affect growth, hormone levels, or
sexual development [21–23]. Statins are effective in
treating the hypercholesterolemia of nephrotic syndrome,
with decreases in total cholesterol levels up to 45% [24].
The long-term benefit of statins on renal function may be
positive. Down stream from glomerular injury, high levels
of urinary protein pass to the renal tubule and are
reabsorbed. Protein reabsorption may injure the renal
tubule. Statins may inhibit this tubular protein reabsorption
and thereby protect from additional renal injury. Whether
statins provide renoprotective effects in children has not
been well studied, but there are several studies in adults
with nondiabetic proteinuria that indicate that statins may
slow GFR decline [25]. In these studies, the greatest benefit
seemed to accrue in patients with the greatest amount of
proteinuria and renal insufficiency. The side effects of statins
have mainly been limited to myopathy and hepatotoxicity
[26, 27].
Drugs in the fibrate class have also been used alone and
in combination to treat hypercholesterolemia in children
with nephrotic syndrome [28]. The use of gemfibrozil with
a statin may increase the incidence of myopathy. Fenofi-
brate, approved for adult use in January 2006, may have
less interaction due different hepatic metabolism [29]. The
long-term safety of fibrates in children has not been well
established.
Alteration of the renin-angiotensin-aldosterone axis
Blood pressure control for children with FSGS targets
values less than or equal to the 90th percentile for age,
gender, and height and is consistent with recommendations
for all children with kidney disease. Evidence from many
trials using angiotensin-converting enzyme inhibitor (ACE-I)
and/or angiotensin receptor blocker (ARB) therapy in
patients with proteinuria indicate that, beyond their anti-
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in a wide variety of renal diseases. Few studies have had
significant numbers of patients with FSGS specifically, and
fewer still have included children with FSGS. In 1988,
Trachtman and Gauthier reported a 50–70% reduction in
proteinuria in children with steroid-resistant nephrotic syn-
drome (SRNS) using ACE-I therapy [30]. Bagga et al. [31],
in a randomized, crossover trial of low-dose (0.2 mg/kg)
vs. high-dose (0.6 mg/kg) enalapril in 25 patients with
SRNS showed dose related responses, with average urine
albumin/creatinine ratio reductions of 33% and 52%, respec-
tively. Blood pressure control was similar between the two
groups. Several other studies of enalapril and ramipril in
children with a variety of proteinuric renal diseases have
confirmed the efficacy of these drugs in reducing proteinuria
in many, but not all, treated children [32–35]. In the Ramipril
Efficacy in Nephropathy (REIN) study, a double-blind study
in adults with nondiabetic nephropathy, treatment with
ramipril seemed to reduce both proteinuria and the rate of
GFR decline more than could be attributed to blood pressure
control alone [36]. Wühl et al., in a similar trial in almost 400
children with hypoplasia/dysplasia (70%) and glomerulopa-
thies (13%), had similar findings [37].
There have been many studies in adults with renal
disease comparing combined ACE-I/angiotensin receptor
blocker (ARB) therapy with monotherapy alone [38, 39].
Though differing in design and findings, overall, the studies
seem to indicate greater reduction in proteinuria without a
greater frequency of side effects [39–41]. Yang et al. [41]
reported greater reduction in proteinuria with combined
therapy in a small group of five children with immuno-
globulin (Ig)A nephropathy and heavy proteinuria, with no
significant side effects noted. The most concerning side
effect of ACE-I and ARB therapy is in females of
childbearing years, with significant risk of fetal abnormal-
ities reported with in utero exposure [42]. Other side effects
of ACE-I therapy were noted in 2.4% of children in one
large series with ramipril in children with chronic renal
failure [37]. These side effects included decreases in GFR
and hemoglobin and increases in serum potassium levels.
Acute renal failure, often associated with hypovolemia, has
been noted and seems to respond to discontinuation of the
medicine until the acute illness resolves. Angioedema and
nonproductive cough have been encountered with the use of
ACE-I therapy in adults and are less frequently reported in
children. ARBs seem to have a lower incidence of angio-
edema and cough [43, 44]. The incidence of recurrent
angioedema in those who experience ACE-I-associated
angioedema and are switched to ARB therapy appears to
be low [45].
Aldosterone inhibitors have shown potential for alter-
ation of the fibrotic mechanisms in animal models of
kidney fibrosis, in the reduction of proteinuria in diabetic
nephropathy, and in proteinuric chronic kidney diseases
[12, 46, 47]. In the later study of 40 patients with a variety
of proteinuric kidney diseases, the combination of ACE-I
and aldosterone inhibitor therapy led to a decrease in mean
urinary protein excretion in the ten patients assigned to this
study arm [48]. Studies in humans with FSGS have not
been published.
Antioxidants
The potential for antioxidant therapy in FSGS stems from
experimental data that supports a role for excessive free
radicals in multiple disease states, including chronic kidney
disease. Based on antioxidant properties, vitamin E has
been evaluated as a potential therapy for FSGS in one small
study by Tahzib et al. In this open-label study, 11 children
with FSGS were treated with vitamin E for approximately
3 months. A reduction in protein excretion was noted [49].
The antioxidant properties of vitamin E and the relatively
low risk for adverse effects of this agent make this an
interesting, if unproven, therapeutic option. The combined
conservative management approach may control morbidity
but leave the majority of patients with uncontrolled urinary
protein excretion and risk for progression of disease. The
typical approach to FSGS therapy in children is to add
immunosuppression at the onset of therapy.
Immunosuppression
Corticosteroids
Corticosteroids have long been the mainstay of treatment for
childhood nephrotic syndrome, regardless of its etiology.
The huge role that these agents play is evident in the way
this disease is classified: steroid responsive, steroid depen-
dent, and steroid resistant. The International Study of Kidney
Disease in Children (ISKDC) standard dosing has been, and
generally continues to be, applied. That is, an 8-week course
of oral prednisone at 60 mg/m
2/day for 4 weeks, followed by
40 mg/m
2 on alternate days for 4 weeks [50]. Initial ISKDC
data showed a corticosteroid response rate of approximately
30% of the 37 children with FSGS studied, and subsequent
studies have been consistent in showing a response to oral
corticosteroids in a minority of FSGS patients [51].
However, a response to corticosteroids is generally consis-
tent with a more favorable prognosis, even when an initial
response is followed by resistance after a subsequent relapse.
There are also reported population differences in the
response to steroid treatment, such as decreased response
in African Americans and Hispanics [52]. Some literature is
emerging that shows a lower response rate for patients with
the nephrosis 2 homolog, podocin (human) (NPHS2)m u t a -
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steroid, how much steroid, and for how long, before a patient
can be definitely declared unresponsive. Certainly, data in
adult patients advocate prolonged oral corticosteroid admin-
istration, in some cases >6 months [54]. There have been no
pediatric trials of prolonged oral corticosteroid use in
patients with FSGS. The regimens used vary tremendously,
with the most dramatic differences occurring between
pediatric nephrologists and internist nephrologists. Due to
the generally poor response to the standard oral dosing, some
pediatric protocols have advocated high doses of intravenous
methylprednisolone, with varying degrees of success [54,
55]. Corticosteroids remain a key component of many
therapeutic regimens for FSGS, usually in combination with
the various other drugs used to treat this disease, such as
alkylating agents or calcineurin inhibitors. Of course,
corticosteroid therapy is not without side effects. These
include hypertension, growth impairment with prolonged
therapy, susceptibility to infection, diabetes mellitus, and
osteoporosis [55]. These side effects have led to the tendency
toward lower corticosteroid doses and shorter, rather than
prolonged, courses.
Calcineurin inhibitors
Cyclosporine A
The rationale behind the initial use of cyclosporine A (CsA)
in FSGS and other forms of nephrotic syndrome is the
evidence in animal models that the disease may be mediated
by lymphokines that mediate glomerular basement mem-
brane damage although it is unclear that this is actually the
case. CsA acts on T-helper cells to inhibit interleukin-2
(IL-2) production, cytotoxic T-cell proliferation, and
activation of B-cell responses by helper T-cells. However,
CsA likely induces remission in proteinuria by two other
mechanisms: induction of vasoconstriction of the glomer-
ular afferent arteriole and interference with glomerular
basement membrane permselectivity to proteins [56].
It has been two decades since CsA was first reported to
show some benefit for patients with idiopathic nephrotic
syndrome, especially for patients with steroid-responsive
disease who had frequent relapses. One randomized trial of
49 steroid-resistant patients assigned to either CsA or
placebo for 6 months showed a benefit in the CsA arm,
with a response rate of 70% (complete or partial remission).
This is the only medication with documented efficacy for
steroid-resistant FSGS in controlled clinical trials in both
adults and children [57, 58]. A major concern of long-term
CsA treatment is the well-documented potential for nephro-
toxicity. Another is the high relapse rate after drug
withdrawal. In the Cattran study [57], 60% of the patients
who responded to treatment had relapsed by week 78.
There is also now concern being raised about secondary
resistance developing in patients treated with CsA: an initial
induction of remission, relapse when the drug is withdrawn,
and resistance on reinstitution of the drug [59]. In this study
of 32 children, the diagnosis of FSGS and the presence of
C4 or C1q during immunofluorescence staining of kidney
tissue appear to correlate with an increased risk of
secondary resistance. There are still no guidelines for
standardized dosing or duration of treatment of children
with steroid-resistant nephrotic syndrome, which probably
accounts for the variability in reported response to
treatment in the literature.
Side effects of CsA treatment include hypertension,
hirsutism, and gingival hyperplasia. As a result of these and
the risk for nephrotoxicity, treatment with cyclosporine has
not been without controversy in terms of perceived optimal
daily dosing, blood level to be maintained, and duration of
treatment. A recent Egyptian study in 117 children with
nephrotic syndrome, which included 79 patients with
FSGS, used low-dose, long-term CsA (more than 2 years
of treatment) [60]. The starting dose of 4–5 mg/kg per day
was adjusted to maintain a whole-blood trough level of
100–150 ng/ml during the first 2 months and 50–100 ng/ml
thereafter. In these subjects with steroid-resistant FSGS, the
investigators were able to achieve an almost 70% complete
remission rate during the 6 months of therapy. Unfortu-
nately, the relapse rate was substantial upon withdrawal of
CsA. Overall, it appears that, as with corticosteroids, a
positive response to CsA, even if followed by a relapse, is a
good prognostic indicator with regard to the risk for
progression to ESRD [57].
Tacrolimus
This newer and more potent calcineurin inhibitor has not
undergone a controlled clinical trial for the treatment of
FSGS, but there are anecdotal reports of responses in
patients with nephrotic syndrome, some of whom had
FSGS [61]. One retrospective study of 16 children with
treatment-resistant nephrotic syndrome, including 13 with
FSGS, documented reduction in urinary protein excretion in
13 while on therapy and subsequent relapse in three of the
13 [62]. There are also two small prospective studies in
adults that showed a positive response [63, 64]. In these
small studies, tacrolimus appeared to present a problem
similar to that of CsA, with a majority of patients relapsing
on drug withdrawal [63].
Alkylating agents
DNA alkylating agents such as cyclophosphamide and
chlorambucil have been in use since the 1980s for several
glomerular diseases, including FSGS. The use of these
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including bone marrow suppression, infertility, hemorrhagic
cystitis, and possible future malignancy risk. A retrospec-
tive cohort of 29 patients suggested that cyclophosphamide
may have some survival benefit in those with at least a
partial response measured by impact on proteinuria and
progression of chronic kidney disease [65]. A randomized
trial in 1996 from the ISKDC evaluated 60 children with
FSGS and their response to daily oral cyclophosphamide
and alternate day prednisone vs. alternate day prednisone
alone. There was no difference in renal survival or
proteinuria between the two groups [66]. Due to unfavor-
able toxic side effects and variable reported efficacy in the
literature, alkylating agents are falling out of favor for
primary therapy in FSGS.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) was introduced in the
mid-1990s as an immunosuppressive agent for organ
transplantation. Due to its steroid-sparing effect, efforts
have been made to expand its clinical application to several
glomerular diseases, including FSGS. MMF blocks de novo
synthesis of T- and B-cell lymphocytes through noncom-
petitive, reversible inhibition of inosine monophosphate
dehydrogenase. Data on the use of MMF in FSGS has been
limited to a few uncontrolled trials with small numbers of
patients, but it shows early promise. Choi et al. reported 46
patients with primary glomerulopathies, including 18 pa-
tients with FSGS. They found a statistically significant
decrease in proteinuria in patients receiving MMF as
adjunctive therapy [67]. Cattran et al. reported an open-
label, 6-month trial of MMF in 18 patients with steroid-
resistant FSGS, 12 of whom were also resistant to
alkylating agents and/or calcineurin inhibitors. Although
patients did not achieve complete remission, four of 18 had
a reduction in proteinuria during therapy [68]. A similar
decrease in proteinuria was documented in a series of nine
children and young adults with steroid-resistant FSGS who
were treated with pulse steroids and MMF [69]. Overall,
MMF is showing early promise as a steroid-sparing therapy
in FSGS, but questions remain about length of therapy,
escalation of dosing, and long-term malignancy risks.
Sirolimus
The utility of sirolimus in the treatment of FSGS has been
entertained in patients with intolerance or resistance to
corticosteroid therapy. One prospective nonrandomized
study documented a reduction of proteinuria in 12 of 21
patients treated with 6 months of sirolimus [70]. Conversely,
a study of six FSGS patients treated with sirolimus
documented a decline in kidney function in five patients.
None had a complete remission [71]. In transplant recipients,
the use of sirolimus in conjunction with calcineurin
inhibitors has also been associated with acute renal failure
[72]. Consequently, sirolimus is not recommended for the
treatment of FSGS due to the associated renal toxicity.
Plasmapheresis
In multiple-drug-resistant primary FSGS, the use of plasma-
pheresis has been considered a rescue option. The generally
accepted rationale is for the removal of a circulating factor
from the plasma that alters glomerular barrier function [73].
In primary FSGS in the native kidneys, two small studies
encompassing 19 patients reported a response rate between
12% and 55% [74, 75]. The best response was seen using a
protocol of plasmapheresis, corticosteroids, and cyclophos-
phamide, making it difficult to attribute the full response to
plasmapheresis alone [75]. A single case report of a child
with resistant disease demonstrated improved proteinuria and
serum creatinine [76]. At present, plasmapheresis is consid-
ered a rescue therapy and is an invasive procedure with
significant risks of infection, hypocalcemia, and bleeding.
Plasmapheresis is considered an option for prevention or
treatment of recurrent FSGS in the transplant recipient based
on uncontrolled studies [77, 78].
Antifibrotic therapy
There are a large number of patients with multiple-drug-
resistant FSGS who are at substantial risk of progression to
ESRD and for whom there are no proven therapeutic
options. The past decade has witnessed striking advances in
understanding the cellular and molecular basis of renal
fibrosis and its contribution to progressive kidney failure.
Several therapeutic targets have been identified in animal
models of fibrosis in the kidney, including molecules
involved in the recruitment and activation of mononuclear
cells (e.g., chemokines, lymphokines, adhesion molecules),
recruitment and activation of interstitial myofibroblasts,
fibrogenic molecules [e.g., transforming growth factor
(TGF)-β, endothelin-1, angiotensin II, tumor necrosis
factor (TNF)-α, and platelet-derived growth factor
(PDGF)-β], angiogenic factors [e.g., vascular endothelial
growth factor (VEGF)], antiapoptotic molecules, inhibitors
of matrix synthesis, and molecules that enhance matrix
degradation (matrix-degrading proteases, blockers of prote-
ase inhibitors) [79–83]. Crossing many of these mecha-
nisms, peroxisome proliferator activator receptor-γ
(PPARγ) agonists alter regulation of renal cell differentia-
tion and proliferation [84–87], extracellular matrix produc-
tion, macrophage accumulation, tissue inflammation, and
apoptosis [88]. The most effective treatment to prevent
progression of fibrosis and kidney failure in FSGS is likely
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fibrosis. The progression of kidney fibrosis is interrupted in
part by the use of ACE-I and ARB agents in FSGS therapy.
Future therapeutic options are likely to emanate from this
area of research.
Conclusions
Current strategies for control of FSGS use a stepwise approach
with a goal of normalization of urinary protein excretion and
the prevention of kidney failure. Progress in this field remains
a priority in order to prevent the trajectory toward renal failure
for patients proven to be resistant to treatment and to identify
therapeutic regimens with minimal toxicity.
CME questions
(Answers appear following the reference list)
1. A 14-year-old boy presents with nephrotic syndrome,
normal serum creatinine, and normal blood pressure.
He is diagnosed with FSGS by kidney biopsy and
treated with corticosteroids. What is the most likely
response to corticosteroids in this setting?
a. Complete remission with corticosteroid therapy
b. Dependence on corticosteroids
c. Failure to respond to corticosteroids but improves
with cyclosporine
d. Failure to control proteinuria and progression
to kidney failure
2. Factors that seem to confer an unfavorable prognosis in
children with nephrotic syndrome are:
a. Primary resistance to corticosteroids
b. Resistance to cyclosporine
c. Presence of NPHS2 podocin mutation
d. African American or Hispanic ethnicity
e. All of the above
3. In the management of FSGS, progressive kidney
fibrosis may be slowed by:
a. Furosemide
b. Angiotensin receptor blockade
c. Cholestyramine
d. Prednisone
e. Both b and d
4. FSGS patients with NPHS2 podocin mutation are more
likely to respond to corticosteroids than patients
without a podocin mutation (T/F).
5. Cyclophosphamide is considered a mainstay in therapy
for FSGS to prevent progression to end-stage renal
failure (T/F).
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